NCT05952934RecruitingPhase 2
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
A Phase II Clinical Trial of Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the placebo arm. The ratio of the number of subjects who will receive Candin versus placebo will be 3:1. Up to 100 subjects will be screened until 80 subjects are eligible for injection.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 3 Jul 2023
- Start date
- 12 Feb 2024
- Primary completion date
- 31 Jul 2032
- Lead sponsor
- University of Arkansas
- Diseases
- Head and neck cancer
- NCT number
- NCT05952934
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 100
- From 12 Feb 2024 to the primary completion date, 31 Jul 2032
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who are allergic to Candin®
Other
- Positive urine pregnancy test for women of childbearing potential
- Being pregnant or attempting to be pregnant with the period of study participation
- Women who are breast feeding or plan to breast feed within the period of study participation
- If in the opinion of the PIs or other Investigators, it is not in the best interest of the patient to enter or continue in this study
Who the study is looking for
- Able to provide informed consent
- Male or female 18 years of age or older
- Squamous cell carcinoma of the head and neck who have completed curative therapy (surgery and/or radiation and/or chemotherapy and/or immunotherapy) within the 120 days prior to the screening visit
- No Evidence of Disease (NED) based on clinical and radiographic evaluations
- Willing and able to comply with the requirements of the protocol
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Highlands Oncology Group, PA Coordinator of this site? Confirm its status | Fayetteville | United States | Recruiting |
| University of Arkansas for Medical Sciences Coordinator of this site? Confirm its status | Little Rock | United States | Recruiting |
| Perlmutter Cancer Center at NYU Langone Health Coordinator of this site? Confirm its status | Mineola | United States | Recruiting |
| Perlmutter Cancer Center at NYU Langone Health Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| Highlands Oncology Group, PA Coordinator of this site? Confirm its status | Rogers | United States | Recruiting |
| Highlands Oncology Group, PA Coordinator of this site? Confirm its status | Springdale | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.